The novel role of Adgrf1 in the progression of fatty liver was revealed and targeting Adgrf1 is a promising therapeutic strategy for treating NAFLD patients.
Harriet Hunter, Dana de Gracia Hahn ... Jake P Mann
Animal studies of fatty liver disease over-estimate the benefit of drugs due to publication bias and are confounded by off-target weight loss, illustrating the challenge of successful translational across species.
MIR20B has a deteriorating effect in NAFLD by suppressing PPARA, and may serve as a therapeutic target for combination therapy with fenofibrate for NAFLD.
Christin Krause, Jan H Britsemmer ... Henriette Kirchner
The liver microRNA transcriptome of humans with type 2 diabetes and obesity is analyzed for the first time and compared with diet-induced obesity in mice.
A system genetics approach reveals a unique molecular signature of non-alcoholic fatty liver disease in mice and identifies novel genetic factors affecting hepatic steatosis.
Meredith A Sommars, Krithika Ramachandran ... Grant D Barish
B cell lymphoma 6 (BCL6) represses fasting gene expression by opposing peroxisome proliferator-activated receptor alpha (PPARa) activity at enhancers, and its ablation protects against steatosis by enhancing fatty acid catabolism.
LncRNA-Snhg3 regulates lipid metabolism by affecting chromatin accessibility which indicates that lncRNA-mediated epigenetic modification has a crucial role in the pathology of metabolic dysfunction-associated fatty liver disease.
Biochemical and genetic studies reveal a third transcription factor, BHLHE40, that together with LXR and C/EBPβ mediates insulin induction of SREBP-1c, which in turn leads to triglyceride accumulation in liver.
Ablation of the G-protein-coupled receptor C3aR1 specifically on macrophages or Kupffer cells does not alter the course of metabolic dysfunction-associated steatotic liver disease in a dietary mouse model.
